Evaluation of Fumagilin-B® and other potential alternative chemotherapies against Nosema ceranae-infected honeybees (Apis mellifera) in cage trial assays
Autor: | Stephen F. Pernal, Simon J. G. Otto, Jonathan M. Curtis, Johan P. van den Heever, Abdullah Ibrahim, T.S. Thompson |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0106 biological sciences
0301 basic medicine [SDV]Life Sciences [q-bio] 01 natural sciences Microbiology 03 medical and health sciences Fumagilin-B chemistry.chemical_compound medicine Fumagillin Enilconazole Thymol chemistry.chemical_classification biology DCH Biological activity biology.organism_classification fumagillin Nosema ceranae apiculture 3. Good health 010602 entomology 030104 developmental biology Nosema Enzyme Biochemistry chemistry Insect Science dicyclohexylamine Fumagilin-B® analogues medicine.drug |
Zdroj: | Apidologie Apidologie, Springer Verlag, 2016, 47 (5), pp.617-630. ⟨10.1007/s13592-015-0409-3⟩ |
ISSN: | 0044-8435 1297-9678 |
DOI: | 10.1007/s13592-015-0409-3⟩ |
Popis: | International audience; AbstractFumagilin-B® is the only currently registered chemical treatment available to combat nosema disease in apiculture. Fumagillol, the basic hydrolysis product of fumagillin, two semisynthetic fumagillin analogues, and four in-house purely synthetic compounds which were designed to mimic the mode of action of fumagillin against the methionine aminopeptidase type 2 (MetAP-2) enzyme, was observed to exhibit statistically significant biological activity against Nosema ceranae-infected caged bees. None of these compounds were, however, as effective as Fumagilin-B®. The commercially available thymol and enilconazole also exhibited activity against N. ceranae, with thymol being the most promising chemical treatment other than Fumagilin-B®. High cumulative bee mortality was associated with the therapeutic dosage of Fumagilin-B® during our study, suggesting the need for continued investigation. |
Databáze: | OpenAIRE |
Externí odkaz: |